相关实验视频

Updated: Jan 17, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

HemoDens:用于凝块形成,收缩和溶解的动力特征的全球血液静止分析仪

Mikael Lund¹, Menikae K Heenkenda², Cia Laine³

¹Department of Biomedical and Clinical Sciences, Linköping University, Sweden; Department of Internal Medicine, Motala Hospital, Motala, Sweden.

Thrombosis research

|September 23, 2025

概括

一个新的HemoDens分析仪允许使用全血进行快速和可重复的凝块收缩 (CR) 评估. 这种标准化试验提供了详细的静血动力学,有助于临床测试和药物监测.

科学领域:

血液静止和血栓形成
血小板生理学血小板生理学
生物医学工程生物医学工程

背景情况:

凝块收缩 (CR) 对于静血至关重要,反映了全球静血功能.
缺乏标准化CR测定,阻碍了临床应用.
血小板动肌素收缩驱动纤维素-血小板凝块的CR.

研究的目的:

开发一种快速,可重复的全血分析仪,用于凝块形成 (CF),CR和外源性凝块溶解 (eCL).
为了使用最小的样本体积,使血液静止的动态表征成为可能.
为了验证HemoDens测试的灵敏度和特异性.

主要方法:

开发了HemoDens全血血静止分析仪.
用于标准化,双端定凝块形成的血小板腔.
采用光密度计来监测CR期间的红细胞再分配.

主要成果:

该HemoDens试验提供了CF,CR和eCL的详细动力学参数.
通过抑制关键的CR途径 (例如,血小板结合,活性蛋白聚合) 来验证测试性能.
对血液计数,抗凝血剂 (肝素,达比加特兰) 和药物 (rtPA),包括逆转剂的敏感性已被证明.

结论:

HemoDens分析仪提供了一种标准化,可重复的方法来评估静血动力学.
这种测定有助于快速表征血块形成,收缩和溶解.
潜在的应用包括临床诊断和抗血栓/抗血栓治疗的监测.

关键词:

血液凝固血液凝固血小板是血液中的血小板.凝块收缩凝块收缩血液静止血液静止血液静止血小板功能测试试验血小板功能测试

更多相关视频

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

相关概念视频

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...